iRhom2 and ADAM17 levels increase during cancer progression and correlate with lower survival rates (Agwae et al., 2020; Borrell-Pagès et al., 2003; Mochizuki and Okada, 2007; Walkiewicz et al., 2016; Xu et al., 2020; Zhou et al., 2006, 2014). Here, RHBDF2 is linked to cancer.